Info

🌱 來自：TLDR_brignole2018ESCGuidelines2018

TLDR_kim_1529p_2019

1. Ahn MJ, Yang JCH, Yu HA, et al. 136O: Osimertinib combined with durvalumab in EGFR-mutant non-small cell lung cancer: Results from the TATTON phase Ib trial. Journal of Thoracic Oncology. 2016;11(4):S115-NA. doi:10.1016/s1556-0864(16)30246-5

1

1. Brignole M, Moya A, de Lange FJ, et al. 2018 ESC Guidelines for the diagnosis and management of syncope. European Heart Journal. 2018;39(21):1883-1948. doi:10.1093/eurheartj/ehy037

NOTE

[[LitNote/kelleyCabozantinibAtezolizumabSorafenib2022.md|Kelley. 2022. Cabozantinib plus atezolizumab versus sorafenib for advanced hepatocellular carcinoma (COSMIC-312): a multicentre, open-label, randomised, phase 3 trial]] Open in Zotero CiteKey🔑: [@kelleyCabozantinibAtezolizumabSorafenib2022]